- Home
- SHIP vs KLRS Comparison
SHIP vs KLRS Comparison
Compare SHIP & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHIP
- KLRS
- Stock Information
- Founded
- SHIP 2008
- KLRS 2019
- Country
- SHIP Greece
- KLRS United States
- Employees
- SHIP N/A
- KLRS N/A
- Industry
- SHIP Marine Transportation
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SHIP Consumer Discretionary
- KLRS Health Care
- Exchange
- SHIP Nasdaq
- KLRS Nasdaq
- Market Cap
- SHIP 131.9M
- KLRS 129.0M
- IPO Year
- SHIP 2007
- KLRS N/A
- Fundamental
- Price
- SHIP $6.48
- KLRS $2.50
- Analyst Decision
- SHIP Strong Buy
- KLRS Buy
- Analyst Count
- SHIP 1
- KLRS 1
- Target Price
- SHIP $11.00
- KLRS N/A
- AVG Volume (30 Days)
- SHIP 109.1K
- KLRS 39.9K
- Earning Date
- SHIP 08-05-2025
- KLRS 08-15-2025
- Dividend Yield
- SHIP 11.75%
- KLRS N/A
- EPS Growth
- SHIP 48.17
- KLRS N/A
- EPS
- SHIP 1.26
- KLRS N/A
- Revenue
- SHIP $153,372,000.00
- KLRS N/A
- Revenue This Year
- SHIP N/A
- KLRS N/A
- Revenue Next Year
- SHIP $21.78
- KLRS N/A
- P/E Ratio
- SHIP $5.12
- KLRS N/A
- Revenue Growth
- SHIP 17.53
- KLRS N/A
- 52 Week Low
- SHIP $4.78
- KLRS $2.28
- 52 Week High
- SHIP $12.65
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- SHIP 50.95
- KLRS N/A
- Support Level
- SHIP $6.11
- KLRS N/A
- Resistance Level
- SHIP $6.74
- KLRS N/A
- Average True Range (ATR)
- SHIP 0.22
- KLRS 0.00
- MACD
- SHIP -0.05
- KLRS 0.00
- Stochastic Oscillator
- SHIP 40.00
- KLRS 0.00
About SHIP Seanergy Maritime Holdings Corp.
Seanergy Maritime Holdings Corp is an international shipping company that provides marine dry bulk transportation services through the ownership and operation of dry bulk vessels. It generates a majority of its revenue from the vessels. The company's fleet of vessels includes Fellowship, Championship, Partnership, Knightship, Lordship, Gloriuship, Leadership, Geniuship, Premiership, and Squireship, among others.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.